| P50 | author | Jay S. Duker | Q112485373 |
| P2093 | author name string | Caio V Regatieri | |
| | Lauren Branchini | |
| P2860 | cites work | Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen | Q27620162 |
| | The biology of VEGF and its receptors | Q27860704 |
| | Prevalence of age-related macular degeneration in the United States | Q29614964 |
| | Optical coherence tomography | Q29617481 |
| | Ranibizumab for neovascular age-related macular degeneration | Q29617549 |
| | Comparison of spectral/Fourier domain optical coherence tomography instruments for assessment of normal macular thickness. | Q30477394 |
| | Neovascular age-related macular degeneration: present and future treatment options. | Q30994746 |
| | Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3. | Q31118256 |
| | Digital indocyanine green videoangiography and choroidal neovascularization. | Q31171910 |
| | Fourier domain mode locking at 1050 nm for ultra-high-speed optical coherence tomography of the human retina at 236,000 axial scans per second | Q33290915 |
| | Multimodal imaging in macular diagnostics: combined OCT-SLO improves therapeutical monitoring | Q33292974 |
| | Optical coherence tomography identification of occult choroidal neovascularization in age-related macular degeneration | Q33294175 |
| | RPE tears after pegaptanib treatment in age-related macular degeneration | Q33300082 |
| | Visualization of 3-D high speed ultrahigh resolution optical coherence tomographic data identifies structures visible in 2D frames | Q33414630 |
| | Analysis of the outer retina reconstructed by high-resolution, three-dimensional spectral domain optical coherence tomography. | Q33421923 |
| | High-speed ultrahigh resolution optical coherence tomography before and after ranibizumab for age-related macular degeneration | Q33438152 |
| | Fourier Domain Mode Locking (FDML): A new laser operating regime and applications for optical coherence tomography | Q33465571 |
| | Assessment of artifacts and reproducibility across spectral- and time-domain optical coherence tomography devices | Q33480756 |
| | Artifacts in automatic retinal segmentation using different optical coherence tomography instruments | Q33525812 |
| | Histopathologic and ultrastructural findings of surgically excised choroidal neovascularization. Submacular Surgery Trials Research Group | Q74696543 |
| | Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1 | Q80553646 |
| | Performance of fourier domain vs. time domain optical coherence tomography | Q83883444 |
| | Do we need a new classification for choroidal neovascularization in age-related macular degeneration? | Q85160758 |
| | Agreement of time-domain and spectral-domain optical coherence tomography with fluorescein leakage from choroidal neovascularization | Q33572472 |
| | Effects of retinal morphology on contrast sensitivity and reading ability in neovascular age-related macular degeneration | Q33606629 |
| | Three-dimensional ultrahigh resolution optical coherence tomography imaging of age-related macular degeneration. | Q33755548 |
| | Three dimensional optical coherence tomography imaging: advantages and advances | Q34233357 |
| | Optical coherence tomography-based decision making in exudative age-related macular degeneration: comparison of time- vs spectral-domain devices | Q34470718 |
| | Ranibizumab versus verteporfin for neovascular age-related macular degeneration. | Q34652928 |
| | The significance of early detection of age-related macular degeneration: Richard & Hinda Rosenthal Foundation lecture, The Macula Society 29th annual meeting | Q34692245 |
| | OCT imaging of choroidal neovascularisation and its role in the determination of patients' eligibility for surgery | Q35309441 |
| | Tracking optical coherence tomography. | Q35921162 |
| | Comparison of ultrahigh- and standard-resolution optical coherence tomography for imaging macular pathology | Q35921294 |
| | Three-dimensional retinal imaging with high-speed ultrahigh-resolution optical coherence tomography | Q35924650 |
| | Active retinal tracker for clinical optical coherence tomography systems | Q36091922 |
| | Optical coherence tomography of age-related macular degeneration and choroidal neovascularization | Q36814558 |
| | High resolution Fourier-domain optical coherence tomography of retinal angiomatous proliferation | Q36973430 |
| | Clinical application of rapid serial fourier-domain optical coherence tomography for macular imaging. | Q36980535 |
| | State-of-the-art retinal optical coherence tomography | Q37013481 |
| | Advanced scanning methods with tracking optical coherence tomography | Q37147729 |
| | Ultrahigh speed spectral / Fourier domain OCT ophthalmic imaging at 70,000 to 312,500 axial scans per second | Q37344925 |
| | Association between foveal photoreceptor integrity and visual outcome in neovascular age-related macular degeneration | Q37425486 |
| | Relationship between optical coherence tomography retinal parameters and visual acuity in neovascular age-related macular degeneration. | Q37684468 |
| | Automatic segmentation in three-dimensional analysis of fibrovascular pigmentepithelial detachment using high-definition optical coherence tomography | Q40159922 |
| | Imaging of the retinal pigment epithelium in age-related macular degeneration using polarization-sensitive optical coherence tomography. | Q41660638 |
| | Accuracy of retinal thickness measurements obtained with Cirrus optical coherence tomography | Q45722335 |
| | Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results. | Q45987977 |
| | Comparison of spectral-domain versus time-domain optical coherence tomography in management of age-related macular degeneration with ranibizumab. | Q46114610 |
| | Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration | Q46122253 |
| | An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration | Q46469410 |
| | Optical coherence tomography: limits of the retinal-mapping program in age-related macular degeneration | Q46520535 |
| | Comparison of fluorescein angiography and optical coherence tomography for patients with choroidal neovascularization after photodynamic therapy | Q46686686 |
| | Spectral-domain optical coherence tomography with multiple B-scan averaging for enhanced imaging of retinal diseases | Q46864770 |
| | Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting. | Q51600225 |
| | Real-time measurement of in vitro flow by Fourier-domain color Doppler optical coherence tomography. | Q51718972 |
| | Three-dimensional imaging of pigment epithelial detachment in age-related macular degeneration using optical coherence tomography, retinal thickness analysis and topographic angiography. | Q51933394 |
| | Improved signal-to-noise ratio in spectral-domain compared with time-domain optical coherence tomography. | Q53648828 |
| | Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group | Q67696853 |
| | Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group | Q67702246 |
| | Prevalence of age-related maculopathy. The Beaver Dam Eye Study | Q68207448 |
| | Age-related macular degeneration | Q69037879 |
| | Occult choroidal neovascularization. Influence on visual outcome in patients with age-related macular degeneration. Macular Photocoagulation Study Group | Q71004401 |
| | Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes | Q71646409 |
| | Choroidal neovascular membranes: reproducibility of angiographic interpretation | Q73314254 |
| | A global initiative for the elimination of avoidable blindness | Q74621234 |
| P304 | page(s) | S56-66 | |
| P577 | publication date | 2011-07-01 | |
| P1433 | published in | Ophthalmic Surgery, Lasers and Imaging | Q15759088 |
| P1476 | title | The role of spectral-domain OCT in the diagnosis and management of neovascular age-related macular degeneration | |
| P478 | volume | 42 Suppl | |